- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.05. | Trump plans $18B NIH budget cut, wants 27 centers consolidated into 5 | ||
| 02.05. | FDA frees Amgen's phase 1 obesity asset from clinical trial hold | ||
| 02.05. | UK unveils £1B plan to become leading cancer research hub just outside the Golden Triangle | ||
| 02.05. | FDA delays decision date on Cytokinetics' heart drug to year-end in unusual safety program back-and-forth | ||
| 02.05. | Pliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woes | ||
| 30.04. | Biopharma VC financing fell 20% in Q1 compared to '24: GlobalData | ||
| 30.04. | Cellectar is seeking strategic alternatives, sinking stock | ||
| 30.04. | Investor pressures Acelyrin to exit Alumis merger and liquidate, slams 'inexplicable' process | ||
| 30.04. | Novartis pays $800M upfront to buy Regulus for phase 3-ready kidney drug | ||
| 30.04. | Entrada lays off 20% of staff weeks after having FDA hold lifted | ||
| 29.04. | Ono Pharma lays off 83 staffers at Cambridge site | ||
| 29.04. | Eli Lilly pens Creyon Bio AI oligonucleotide pact with $1B in biobucks on the table | ||
| 29.04. | FDA misses PDUFA date for Stealth's ultra-rare disease candidate, delaying approval decision-again | ||
| 29.04. | Octagon shuts down after R&D challenges put it behind the 8 ball | ||
| 29.04. | AstraZeneca culls a Lilly-partnered Alzheimer's drug alongside 2 other neuroscience meds in Q1 clear-out | ||
| 29.04. | Novartis axes osteoarthritis asset and radioligand therapy after seeing clinical data | ||
| 28.04. | Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M | ||
| 28.04. | Ferrer inks licensing deal worth up to €500M for Prilenia's ALS asset | ||
| 28.04. | HHS lifts stop work order on Vaxart's COVID-19 trial, continues funding for the 10,000-participant study | ||
| 28.04. | Novo Holdings dials back investment as Trump stymies economic forecasters | ||
| 28.04. | Tonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woes | ||
| 28.04. | Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA | ||
| 28.04. | Pfizer ties PD-1 drug to 32% bladder cancer risk reduction in mixed bag phase 3 as it misses secondaries | ||
| 25.04. | ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials | ||
| 25.04. | M&A remains 'top priority' for Big Pharmas in the face of tariff threat |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .